These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8579803)

  • 1. D2-receptor imaging with [123I]IBZM and single photon emission tomography in psychiatry: a survey of current status.
    Schlösser R; Schlegel S
    J Neural Transm Gen Sect; 1995; 99(1-3):173-85. PubMed ID: 8579803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
    Scherfler C; Scholz SW; Donnemiller E; Decristoforo C; Oberladstätter M; Stefanova N; Diederen E; Virgolini I; Poewe W; Wenning GK
    Neuroimage; 2005 Feb; 24(3):822-31. PubMed ID: 15652317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.
    Leslie WD; Abrams DN; Greenberg CR; Hobson D
    J Nucl Med; 1996 Oct; 37(10):1589-91. PubMed ID: 8862288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
    Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM
    J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
    Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ
    Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS).
    Staedt J; Stoppe G; Kögler A; Riemann H; Hajak G; Munz DL; Emrich D; Rüther E
    J Neural Transm Gen Sect; 1995; 99(1-3):187-93. PubMed ID: 8579804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas.
    de Herder WW; Reijs AE; de Swart J; Kaandorp Y; Lamberts SW; Krenning EP; Kwekkeboom DJ
    Eur J Nucl Med; 1999 Jan; 26(1):46-50. PubMed ID: 9933661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
    de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of scatter correction on D2 receptor occupancy measurements using 123I-IBZM SPECT: comparison to 11C-Raclopride PET.
    Bullich S; Cot A; Gallego J; Gunn RN; Suárez M; Pavía J; Ros D; Laruelle M; Catafau AM
    Neuroimage; 2010 May; 50(4):1511-8. PubMed ID: 20083205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
    Seibyl JP; Zea-Ponce Y; Brenner L; Baldwin RM; Krystal JH; Offord SJ; Mochoviak S; Charney DS; Hoffer PB; Innis RB
    J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial experience with SPECT examinations using [123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease.
    Cordes M; Henkes H; Laudahn D; Bräu H; Kramp W; Girke W; Hierholzer J; Eichstädt H; Felix R
    Eur J Radiol; 1991; 12(3):182-6. PubMed ID: 1830273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
    Hierholzer J; Cordes M; Schelosky L; Barzen G; Poewe W; Henkes H; Keske U; Horowski R; Felix R
    Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W; Grundmann M; Huber G
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT.
    Schelosky L; Hierholzer J; Wissel J; Cordes M; Poewe W
    Mov Disord; 1993 Oct; 8(4):453-8. PubMed ID: 8232354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography.
    van Royen E; Verhoeff NF; Speelman JD; Wolters EC; Kuiper MA; Janssen AG
    Arch Neurol; 1993 May; 50(5):513-6. PubMed ID: 8489409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.
    Jauss M; Krack P; Franz M; Klett R; Bauer R; Gallhofer B; Dorndorf W
    Mov Disord; 1996 Nov; 11(6):726-8. PubMed ID: 8914102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D2 receptor occupancy measured by single photon emission computed tomography with 123I-Iodobenzamide in chronic schizophrenia.
    Volk S; Maul FD; Hör G; Schreiner M; Weppner M; Holzmann T; Pflug B
    Psychiatry Res; 1994 Jun; 55(2):111-8. PubMed ID: 10711799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Test-retest variability and reliability of 123I-IBZM SPECT measurement of striatal dopamine D2 receptor availability in healthy volunteers and influence of iterative reconstruction algorithms.
    Catafau AM; Bullich S; Danús M; Penengo MM; Cot A; Abanades S; Farré M; Pavía J; Ros D
    Synapse; 2008 Jan; 62(1):62-9. PubMed ID: 17960766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study.
    Verstappen CC; Bloem BR; Haaxma CA; Oyen WJ; Horstink MW
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):502-7. PubMed ID: 17053905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism.
    Schwarz J; Antonini A; Tatsch K; Kirsch CM; Oertel WH; Leenders KL
    Nucl Med Commun; 1994 Oct; 15(10):806-13. PubMed ID: 7838444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.